Search Results 71-80 of 23128 for B cell lymphomas
Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-cell Lymphoma · Overview · Participation eligibility.
Research. Mayo Clinic doctors and researchers are studying diffuse large B-cell lymphoma to look for new ways to improve diagnosis and treatment for this ...
The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.
Mayo Clinic doctors and researchers are studying cutaneous B-cell lymphoma to look for new ways to improve diagnosis and treatment for this cancer. Cancer ...
A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell ...
A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma · More about research at Mayo Clinic.
Among non-Hodgkin lymphomas, the most common is diffuse large B-cell lymphoma, which represents about 30 percent of all lymphomas in the U.S.. Committed to ...
Histologically proven large B-cell lymphoma including the following types defined by WHO 2016 (Swerdlow et al., 2016): · Relapsed or refractory disease after ...
Clinical Trials · Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in High-Risk Large B-Cell Lymphoma · More about research at Mayo ...
Moustafa and his co-author outlined the effectiveness of CAR-T cell therapy in extranodal diffuse large B-cell lymphoma (DLBCL), noting that it presents a " ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.